Indaptus Therapeutics (INDP) Stock Forecast: StockMap's 2-Week Call
INDP stock forecast: StockMap's model makes no two-week call on Indaptus Therapeutics after the Nov 19 close: its evidence is split, 4 reasons for and 9 against. Right in 3 of 6 two-week windows on INDP since Aug 21; by chance, a call on the same dates was right 59% of the time.
Indaptus Therapeutics last closed at $3.13, -4.86% on the session.
Against the IVW growth benchmark the position is -2.53% over the forecast window.
Indaptus Therapeutics' market cap is $480.79M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 6 (too close to call).
Where INDP sits: sized by market cap, coloured by the day's move.
The read is built from 13 underlying insights — 4 bullish and 9 bearish.
Agreement across those insights is 31%.
41 daily calls for INDP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Indaptus Therapeutics in the 3rd percentile on return on equity, where 100 is best.
Indaptus Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Indaptus Therapeutics as the 174th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Indaptus Therapeutics ranks 44th of 394 in the group, against a group median of -0.27.